AmerisourceBergen names EVP, president of AmerisourceBergen Drug
VALLEY FORGE, Pa. — AmerisourceBergen announced on Wednesday that Robert Mauch has been promoted to EVP and president of AmerisourceBergen Drug, effective immediately.
Previously, Mauch served as AmerisourceBergen Drug’s SVP and COO. David Neu will transition from his previous role as president of AmerisourceBergen Drug to assume the newly created position of EVP of Retail Strategy and President of Good Neighbor Pharmacy.
“Bob has demonstrated tremendous leadership and his powerful strategic thinking has played a significant role in enabling AmerisourceBergen to deliver on our promise to be a global healthcare solutions leader,” said Steven Collis, AmerisourceBergen’s president and CEO. “In his new role, Bob’s innovative, customer-centric vision will further our efforts to support pharmaceutical manufacturers and healthcare providers as they work to drive the best outcomes for patients.”
“I am very pleased that Dave will focus his considerable energy and expertise on further strengthening AmerisourceBergen’s programs and services for retail pharmacy,” continued Collis. “The evolving healthcare landscape has created unprecedented opportunities to elevate the role of community pharmacy. With Dave’s long standing commitment to Good Neighbor Pharmacy and the independent pharmacists we serve, combined with his demonstrated leadership in fostering innovative partnerships throughout the pharmaceutical supply chain, we are very well positioned to continue to drive tremendous value for all of our stakeholders.”
Prior to his role as COO of AmerisourceBergen Drug, Mauch served AmerisourceBergen in numerous positions. He was the founder and president of Xcenda, which was acquired by AmerisourceBergen in 2007, and has held various leadership positions at AmerisourceBergen, including SVP, ABDC Alternate Care Sales; SVP, ABDC Sales and SVP, ABDC Operations.
Neu has more than 30 years of industry experience holding senior positions at General Foods, The L.A. Drug Co., Bergen Brunswig and eventually AmerisourceBergen Drug.